| Schedule of Rollforward of Intangible Assets |
A rollforward of the Company's intangible assets for the six months ended June 30, 2026 and 2025 is as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Intangible Asset | | December 31, 2025 | | Additions | | Amortization | | June 30, 2026 | | Acquired ARIKAYCE R&D | | $ | 23,038 | | | $ | — | | | $ | (2,425) | | | $ | 20,613 | | | PARI milestones | | 962 | | | — | | | (101) | | | 861 | | | AstraZeneca milestones | | 44,051 | | | — | | | (1,636) | | | 42,415 | | | Acquired IPR&D | | 29,600 | | | — | | | — | | | 29,600 | | | | $ | 97,651 | | | $ | — | | | $ | (4,162) | | | $ | 93,489 | | | | | | | | | | | | Intangible Asset | | December 31, 2024 | | Additions | | Amortization | | June 30, 2025 | | Acquired ARIKAYCE R&D | | $ | 27,888 | | | $ | — | | | $ | (2,425) | | | $ | 25,463 | | | PARI milestones | | 1,164 | | | — | | | (101) | | | 1,063 | | | Acquired IPR&D | | 29,600 | | | — | | | — | | | 29,600 | | | | $ | 58,652 | | | $ | — | | | $ | (2,526) | | | $ | 56,126 | |
|